A group of 149 patients with cultures resistant to one or more of the primary antituberculosis drugs was treated with the secondary antituberculosis drugs for 6 months or more.
Of whole patients 25.8% became sputa negative on smear and culture.
Of the patients treated with secondary drugs in combination with primary drugs 26.8% became negative.
In the group treated with three drugs 34.8%. and with two drugs 15.6% became negative. Three drugs treatment is more effective than two drugs.
One group had one secondary drug in combination with two primary drugs and 29.8% became negative. Another group had two secondary drugs and one primary drug and 45% became negative. The third group had three secondary drugs only and 44.4% became negative.
One group of streptomycin resistance patients was treated with one of the secondary drugs in combination with isoniazid and PAS, and 16.8% became negative. Another group of streptomycin resistance patients was treated with two secondary drugs in combination with isoniazid and 40% became negative.
The 33 patients treated with secondary drugs for 6 months and had positive cultures had been continued to have same treatment for 8 to 12 months length and only one of them beame negative. The 14 patients who became the sputa negative had been continued to have same treatment and 5 of them became again positive.
In the first treatment group with the secondary drugs 30.4% became negative, and in the re-treatment group 20.3% became negative. First treatment was better than re-treatment.
Radiographic improvement occured in 13.4% of noncavernous diseases, and in 10.5% of cavities.
Treatment was interrupted because of drug toxicity in 16.1% of the whole patients. In this series pyrazinamide has been stopped because of toxic effect in 27.8% of cases, ethionamide in 15.4%. cyclocerine in 8.3%, and kanamycin in 1.7%.
Joint-pain by pyrazinamide, jaundice by ethionamide, aberration by cyclocerine were most unpleasant symptomes to patients. One patient with jaundice by ethionamide died. These toxic effects are abstacles of treating patients wtih the secondary antituberculosis drugs.
抄録全体を表示